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Already in 1863 Rudolph Virchow hypothesized 
that some classes of irritants, together with tissue injury, 
enhance cell proliferation and that cancer arises from 
sites of chronic inflammation. Although now we know 
that cell proliferation is not a cause of cancer on itself, 
for the first time his hypothesis suggested a link between 
cell  transformation  and  inflammation.  Many  tumors 
contain activated fibroblasts and macrophages displaying 
an inflammatory gene expression profile. Interestingly, 
quantitative aspects of wound repair or inflammatory gene 
expression often negatively correlate with cancer stage 
and prognosis: in a sense, tumors act as wounds that fail 
to heal [1].
Chronic  inflammatory  states  may  generate  a 
microenvironment favoring genomic lesions and fostering 
tumor initiation. The presence of free radicals, such as 
reactive oxygen intermediates and nitric oxide, leads to 
oxidative damage and nitration of DNA bases, which 
in turn increases the risk of mutations. Moreover, the 
soluble mediators secreted by inflammatory cells such 
as  cytokines  and  growth  factors  provide  survival  and 
proliferative signals to initiated cells, thereby leading to 
tumor promotion/progression.
More detailed insights into the role of inflammation 
in tumor promotion come from several studies involving 
the  transcription  factor  NF-κB.  For  example,  NF-κB 
inactivation dramatically decreased tumor size of myeloid 
cells in a colitis-associated cancer model, reducing the 
expression of pro-inflammatory cytokines that may serve 
as tumor growth factors [2].
NF-κB  is  a  ubiquitous  transcription  factor  that 
regulates genes involved in native and adaptive immune 
responses.  Importantly,  NF-κB  is  often  aberrantly 
activated in human cancers, up-regulating genes involved 
in the control of survival and proliferation, and is thus 
considered an important target for drug therapies [3]. A 
prominent NF-κB target is the gene encoding for the pro-
inflammatory cytokine IL-6, which directly affects cancer 
cells growth and survival through the activation of another 
transcription factor, the Signal Transducer and Activator 
of Transcription (STAT) 3. Indeed, chronic inflammation 
initiates a positive loop between the transcription factor 
NF-κB, IL-6 and STAT3 that is a highly predisposing 
condition for cancer, particularly in the colon, the liver 
and the breast [4].
STAT3 is constitutively activated by phosphorylation 
on tyrosine in many tumors that often become addicted 
to its activity [5], and is accordingly often referred to 
as an oncogene, even though activating mutations are 
rare. Importantly, STAT3 is prominently constitutively 
activated at sites of chronic inflammation, where IL-6 
levels are invariably high. In an effort to characterize 
the pro-oncogenic functions of continuous, weak STAT3 
activation,  we  have  recently  generated  knock-in  mice 
expressing  physiological  levels  of  the  constitutively 
active  STAT3C  mutant  form  [6].  Primary  mouse 
embryonic fibroblasts (MEFs) derived from the STAT3C/C 
mice  show  pre-malignant  features,  such  as  increased 
glycolysis, resistance to apoptosis and senescence and 
accelerated  proliferation  [7].  When  challenged  with 
a second ‘random’ mutation induced through the 3T3 
spontaneous immortalization protocol, STAT3C/C MEFs 
become fully transformed and are able to form tumors in 
immunocompromised mice [8]. STAT3C/C cells display 
an accelerated cell cycle, protection from apoptosis and 
enhanced HIF-1α-dependent aerobic glycolysis. HIF-1α 
silencing normalizes their glycolysis levels, correlating 
with decreased cell proliferation and growth, both in vitro 
and in vivo.
This  finding  is  of  particular  relevance  for  the 
emerging  key  role  of  STAT3  in  inflammation-driven 
cancer. Therefore, in addition to the tumor promotion role 
described above in coordination with IL-6 and NF-κB, our 
data suggest  that cells exposed to chronic IL-6 signaling, 
which  leads  to  continuous  STAT3  activation  like  that 
displayed by the STAT3C/C MEFs, can behave like cells 
that have undergone a first oncogenic mutation. This first 
hit provides survival and proliferative signals by inducing 
pro-proliferative and anti-apoptotic genes and switching 
cell  metabolism  towards  aerobic  glycolysis,  believed 
to sustain the anabolic metabolism required by tumor 
cells. All  these  features  contribute  to  a  pre-malignant 
state where a second mutation is sufficient to provide 
full cell transformation. Interestingly, a state of chronic 
inflammation with IL-6 accumulation develops with age 
in mice, primates and humans [9]. This may in turn result 
in increasingly high chronic STAT3 activation and thus 
the development of STAT3-dependent tumors. Therapeutic 
strategies focusing on STAT3 modulation could therefore 
dramatically decrease the incidence of age-related cancers, 
lowering the accumulation of the pre-malignant cells pool 
with aging. 
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